# **Eye Therapies Company Profile: Valuation & Investors**



#### **Eye Therapies Overview**

- Founded
- 2010



- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- \$5.82M

### **Eye Therapies General Information**

Description

Developer of ocular pharmaceuticals intended to treat ocular redness. The company offers a technology that may lead to a faster, more effective, and longer-lasting treatment for ocular redness and also create an opportunity to explore expanded ophthalmic applications, helping researchers in ophthalmic product development.

**Contact Information** 

**Ownership Status** 

Privately Held (backing)

**Financing Status** 

Venture Capital-Backed

**Primary Industry** 

Pharmaceuticals



#### **Other Industries**

**Drug Discovery** 

#### **Primary Office**

- 26933 Camino De Estrella
- 2nd Floor
- Dana Point, CA 92624
- United States

+1 (949) 000-0000

### Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Are you a startup? Learn about PitchBook for startups. »

#### Want to dig into this profile?

We'll help you find what you need

Learn more

#### **Eye Therapies Valuation & Funding**

Deal Type	Date	Amount	Raised to Date	Post- Val	Status	Stage
1. Early Stage VC	17-Dec- 2012	\$5.82M	00.000		Completed	Generating Revenue

To view Eye Therapies's complete valuation and funding history, request access »

#### **Eye Therapies Patents**

• 73

**Total Documents Applications and Grants** 

• 000

**Total Patents Families** 



• 3

Granted

• 6

Pending

• 000

Expiring in next 12 mo

## **Eye Therapies Recent Patent Activity**

Publication ID	Patent Title	Status	First Filing Date	Technology (CPC)	Citations
US- 20220031739- A1	Anti-viral compositions and methods of use thereof	Pending	31-Jul- 2020	000000000	
US- 20210338666- A1	Brimonidine combinations and uses thereof	Pending	30- Apr- 2020	000000000	
US- 20190374537- A1	Low-dose brimonidine combinations and uses thereof	Abandoned	07- Jun- 2018	0000000000	0
US-11026884- B2	Methods for improving vision	Active	24- Jan- 2018	0000000000	0
US- 20210259962- A1	Methods for improving vision	Pending	24- Jan- 2018	A61K9/0048	

To view Eye Therapies's complete patent history, request access »

# **Eye Therapies Executive Team (4)**

Name	Title	Board Seat	Contact Info
Lee Nordan MD	Chief Executive Officer, President and Manager		
Robert Rowlett	Co-Founder, Chief Financial Officer, Manager, Treasurer and Secretary		



Name	Title	Board Seat	Contact Info
Gerald Horn	Co-Founder		

You're viewing 3 of 4 executive team members. Get the full list »

## Ready to get started?

Request a free trial

